Woodline Partners’s ResMed RMD Stock Holding History

Woodline Partners’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.28M	Buy	5,693 +3,024	+113%	+$754K	﹤0.01%	854
2025 Q4	$643K	Buy	+2,669	New	+$683K	﹤0.01%	881
2023 Q2	–	Sell	-113,986	Closed	-$25M	–	733
2023 Q1	$25M	Buy	113,986 +69,104	+154%	+$15M	0.34%	89
2022 Q4	$9.34M	Buy	+44,882	New	+$9.86M	0.13%	225
2020 Q2	–	Sell	-46,284	Closed	-$6.82M	–	181
2020 Q1	$6.82M	Buy	+46,284	New	+$7.37M	0.49%	68

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Woodline Partners's RMD Position: Q1 2026 in Review

Woodline Partners increased its ResMed (RMD) stake by 113% in Q1 2026, buying an estimated $754K and bringing the position to 5,693 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #854.

Woodline Partners first reported a position in RMD in Q1 2020 and has held it in 5 quarters since. The position peaked at $25M in Q1 2023. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Woodline Partners held 5,693 shares of ResMed worth $1.28M as of Q1 2026.
Woodline Partners bought 3,024 ResMed shares in Q1 2026, an estimated $754K.
ResMed made up ﹤0.01% of Woodline Partners's portfolio in Q1 2026, its #854 holding.
Woodline Partners first reported a position in ResMed in Q1 2020 and has held it in 5 quarters since.
Woodline Partners's ResMed position peaked at $25M in Q1 2023.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.